Susanna has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies. In her most recent position, she served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the company’s severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO®, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Susanna worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Susanna holds an M.S. in economics and business management from Bocconi University in Italy and an M.B.A. from the MIT Sloan School of Management.
My work style
How I prefer to work
Qualities I value in my colleagues
Sign up to see more about the team at Dyne Therapeutics
My pet peeves
My communication style